All Stories

  1. Prolactin/Stat5 and Androgen R1881 Coactivate Carboxypeptidase-D Gene in Breast Cancer Cells

    Article • Molecular Endocrinology, March 2014, Endocrine Society

    Lynn N Thomas

  2. Carboxypeptidase-D is elevated in prostate cancer and its anti-apoptotic activity is abolished by combined androgen and prolactin receptor targeting

    Article • The Prostate, February 2014, Wiley

    Lynn N Thomas

  3. Progestin-inducible EDD E3 ubiquitin ligase binds to α4 phosphoprotein to regulate ubiquitination and degradation of protein phosphatase PP2Ac

    Article • Molecular and Cellular Endocrinology, January 2014, Elsevier

    Lynn N Thomas

  4. Abstract 86: Prolactin and testosterone induction of carboxypeptidase-D to promote cell survival is greater in prostate cancer cells than benign prostate cells, and their synergistic action in prostate cancer cells is effectively blocked by receptor an...

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Lynn N Thomas

  5. Testosterone and prolactin increase carboxypeptidase-D and nitric oxide levels to promote survival of prostate cancer cells

    Article • The Prostate, June 2011, Wiley

    Lynn N Thomas

  6. Overexpression of 5α-reductase type 1 increases sensitivity of prostate cancer cells to low concentrations of testosterone

    Article • The Prostate, May 2009, Wiley

    Lynn N Thomas

  7. Effect of Steroid 5α-Reductase Inhibitors on Markers of Tumor Regression and Proliferation in Prostate Cancer

    Article • January 2009, Springer Science + Business Media

    Lynn N Thomas

  8. Type 1 and Type 2 5α-Reductase Expression in the Development and Progression of Prostate Cancer

    Article • European Urology, February 2008, Elsevier

    Lynn N Thomas

  9. Levels of 5α-Reductase Type 1 and Type 2 are Increased in Localized High Grade Compared to Low Grade Prostate Cancer

    Article • The Journal of Urology, January 2008, Elsevier

    Lynn N Thomas

  10. Fetal Distribution of 5α-Reductase 1 and 5α-Reductase 2, and Their Input on Human Prostate Development

    Article • The Journal of Urology, August 2007, Elsevier

    Lynn N Thomas, Dr Consolato M. Sergi

  11. The effects of the dual 5α-reductase inhibitor dutasteride on localized prostate cancer—results from a 4-month pre-radical prostatectomy study

    Article • The Prostate, January 2006, Wiley

    Lynn N Thomas

  12. RE: EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER

    Article • The Journal of Urology, April 2005, Elsevier

    Lynn N Thomas

  13. Differential alterations in 5?-reductase type 1 and type 2 levels during development and progression of prostate cancer

    Article • The Prostate, January 2005, Wiley

    Lynn N Thomas

  14. EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER

    Article • The Journal of Urology, September 2004, Elsevier

    Lynn N Thomas

  15. Dutasteride, the dual 5?-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line

    Article • The Prostate, February 2004, Wiley

    Lynn N Thomas

  16. 5α-Reductase Type 1 Immunostaining is Enhanced in Some Prostate Cancers Compared With Benign Prostatic Hyperplasia Epithelium

    Article • The Journal of Urology, November 2003, Elsevier

    Lynn N Thomas

  17. Distribution and activity of 5 alpha-reductase isoenzymes in benign prostatic hyperplasia and prostate cancer

    Article • European Urology Supplements, September 2003, Elsevier

    Lynn N Thomas

  18. Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5

    Article • The Prostate, February 2000, Wiley

    Lynn N Thomas

  19. Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5

    Article • The Prostate, February 2000, Wiley

    Lynn N Thomas

  20. THE UTILITY OF TISSUE TRANSGLUTAMINASE AS A MARKER OF APOPTOSIS DURING TREATMENT AND PROGRESSION OF PROSTATE CANCER

    Article • The Journal of Urology, December 1999, Elsevier

    Lynn N Thomas

  21. Androgen-Induced Regrowth in the Castrated Rat Ventral Prostate: Role of 5α-Reductase1

    Article • Endocrinology, October 1999, Endocrine Society

    Lynn N Thomas

  22. Insulin-like growth factor binding protein 5 is associated with involution of the ventral prostate in castrated and finasteride-treated rats

    Article • The Prostate, June 1998, Wiley

    Lynn N Thomas

  23. Insulin‐like growth factor binding protein 5 is associated with involution of the ventral prostate in castrated and finasteride‐treated rats

    Article • The Prostate, June 1998, Wiley

    Lynn N Thomas

  24. Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat.

    Article • Journal of Clinical Investigation, December 1996, American Society for Clinical Investigation

    Lynn N Thomas

  25. Apoptosis is the mode of keratinocyte death in cutaneous graft-versus-host disease

    Article • Journal of the American Academy of Dermatology, August 1996, Elsevier

    Lynn N Thomas

  26. Evidence for atrophy and apoptosis in the prostates of men given finasteride.

    Article • The Journal of Clinical Endocrinology & Metabolism, February 1996, Endocrine Society

    Lynn N Thomas

  27. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride.

    Article • Endocrinology, February 1995, Endocrine Society

    Lynn N Thomas